36^th World Cancer Conference October 11-13, 2018 Venue: Hilton Zurich Airport, Hohenbühlstrasse 10, 8152 Opfikon, Switzerland

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.

Cancer research, Charged particle optics and Early detection of cancer and delayed detection of cancer.

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Acupunture & Electro-Therapeutics Research, Integrative Oncology

Homer S. Black is a Professor of Dermatology, Baylor College of Medicine, Houston, Texas (1968- 2003).He is a Research Physiologist and Director of the Photobiology Laboratory at the Veterans Affairs Medical Center in Houston. Dr. Black earned a Ph.D. in biochemistry from Louisiana State University in 1964. He earned a B.Sc. in animal science from Texas A&M University in 1956 after which he served with the U.S. Air Force in Strategic Air Command and holds a M.Ed. from Sam Houston State University; and a M.S.Admin. (business/health science management) from the University of Houston. He was a Senior Fulbright Scholar at the Photobiology Centre, University of Dundee, Scotland. . He served as Treasurer in the latter. Dr. Black is also a member of the Institute of Professional Managers and was Chairman of the Board of Regents for the Academy of Administrative Managers.

Pro-carcinogenic effects of antioxidants and dietary fat in UV-carcinogenesis. The experimental studies culminated in a dietary intervention trial in which it was shown that a low-fat dietary intervention reduced the risk for subsequent skin cancers in skin cancer patients.

The central theme of Gary Stein’s research has been to discover mechanisms controlling proliferation and differentiation emphasizing compromised regulation linked with disease. His lab characterizes transcriptional regulation that mediates cell cycle control, focusing on molecular mechanisms regulating gene expression at the G1/S phase transition in normal and tumor cells and the abbreviated pluripotent cell cycle in human embryonic stem cells. He has a major commitment to investigating bone tissue specific gene expression, including microRNA-mediated control, within the context of skeletal development and bone remodeling as well as aberrations that accompany the onset and progression of skeletal disease. The Stein lab is defining functional relationships between the subnuclear organization of regulatory proteins and gene expression, pursuing mechanisms that support combinatorial organization and assembly of regulatory machinery in nuclear microenvironments and epigenetic control of cell fate and lineage commitment in biological control and cancer.

Cell proliferation, differentiation, cell cycle control

Dr. Phillips is a national leader in the treatment of hematologic malignancies and is an innovator in bringing transplant modalities to lymphoma. He is a graduate of the University of Oklahoma School of Medicine where he completed his internship in internal medicine. He continued his residency training at the University of North Carlina School of Medicine and trained at Washington University School of Medicine with a clinical and research fellowship in hematology/oncology. He previously directed the transplant programs at the University of Maryland, University of Kentucky, theUniversity of British Columbia, and Barnes Hospital at the Washington University School of Medicine. Dr. Phillips was the principal investigator of the National Cancer Institute (NCI) study "Improving the Ability of (High-Risk) Hematologic Malignancy Patients to Undergo Allogenic Stem Cell Transplantation".

Hematologic malignancies, Allogenic Stem Cell Transplantation,Internal medicine,Lymphoma.

Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Ovarian cancer, liver cancer.

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971). Dr. Yamaguchi is engaged in the fields of bone and calcium endocrinology and cell calcium signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis. Moreover, Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001) in mammalian cells. Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents (USA, EU, Japan, and Korea), and this animal is found to induce osteoporosis and hyperlipidemia. Recently, Dr. Yamaguchi proposes that regucalcin is a target molecule in carcinogenesis of various cancer cell types. Currently, the research of regucalcin is focused as a scientific topic. Dr. Yamaguchi published over 500 English articles to professional journals with peer-review. In addition, Dr. Yamaguchi registered over 20 national and international patents in the fields of his research interesting. Dr. Yamaguchi is serving as editors and editorial board members of reputed 40 international Journals. He received many honor and awards; Prize for Sato Memorial Fundation (1992, Japan/USA), Senji Miyata Foundation Award 2005 (Japan), Japan Society for Biomedical Research on Trace Elements Award 2007, The Lifetime Achievement Award from International Biographical Centre (IBC) (2004, England), The World Lifetime Achievement Award from American Biographical Institute (2004, USA), The Distinguished Service to Science Award from IBC (2007, England), and many others. Dr. Yamaguchi is listed in various biographies; Who’s Who in the World (2005-, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004-, Marquis Who’s Who, USA), International Biographical Dictionary (2006-, IBC, England), and others.

Cancer and Oncology, Toxicology, Pharmacology

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Chulso Moon is having 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Cancer gene therapy.

Mong-Hong Lee is currently Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997). After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles.

Characterizing the roles of Cdk inhibitors (CKIs) in cancer formation, and exploiting signaling regulation in cancer therapy. Research projects focusing on: 1) roles of two CKI molecules that he cloned in tumorigenesis; 2) COP9 signalosome signaling regulation; 3) investigating the impact of hypoxia and PIm1 kinase in drug resistance; 4) employing Aurora B kinase inhibitor for cancer therapy; 5) p53-MDM2 signaling regulation and DNA damage; 6) Myc ubiquitination regulation; 7) Glycolysis and cancer metabolism.

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing gene-environment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumors, soft-tissue sarcomas, and HPV-related cancers. Additionally, he is founding co-chair for the advances in Bioinformatics and Genomics Symposium series. Dr. Efird has over 100 publications in scientific journals and proceedings.